Do analysts rate NNVC or PCSA?

Heatwurx has a consensus target price of $25.00, suggesting a potential upside of 1,052.07%. Given Heatwurx's higher possible upside, analysts clearly believe Heatwurx is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, NNVC or PCSA?

NanoViricides is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A Heatwurx N/A N/A -$13.56M -$9.29 N/A

Is NNVC or PCSA more profitable?

NanoViricides' return on equity of -87.90% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Heatwurx N/A -281.31% -200.80%

Do analysts prefer PCSA or LITS?

Heatwurx presently has a consensus price target of $25.00, indicating a potential upside of 1,052.07%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than Lite Strategy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lite Strategy 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PCSA or LITS more profitable?

Lite Strategy's return on equity of -90.81% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Lite Strategy N/A -90.81% -89.33%

Do analysts rate CPHI or PCSA?

Heatwurx has a consensus target price of $25.00, indicating a potential upside of 1,052.07%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts clearly believe Heatwurx is more favorable than China Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CPHI or PCSA more profitable?

Heatwurx has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% Heatwurx N/A -281.31% -200.80%

Is PCSA or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Tvardi Therapeutics N/A -64.17% -43.90%

Is PCSA or CRVO more profitable?

Heatwurx has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% CervoMed -672.80% -136.08% -112.62%

Heatwurx (PCSA) Competitors

$2.30 +0.13 (+6.04%)

As of 10:16 AM Eastern

Compare

PCSA vs. NNVC, LITS, CPHI, TVRD, and CRVO

Should you buy Heatwurx stock or one of its competitors? MarketBeat compares Heatwurx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heatwurx include NanoViricides (NNVC), Lite Strategy (LITS), China Pharma (CPHI), Tvardi Therapeutics (TVRD), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.

How does Heatwurx compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

NanoViricides is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

NanoViricides has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

10.3% of NanoViricides shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Comparatively, 2.4% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Heatwurx has a consensus target price of $25.00, suggesting a potential upside of 1,052.07%. Given Heatwurx's higher possible upside, analysts clearly believe Heatwurx is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Heatwurx had 1 more articles in the media than NanoViricides. MarketBeat recorded 1 mentions for Heatwurx and 0 mentions for NanoViricides. Heatwurx's average media sentiment score of 1.87 beat NanoViricides' score of 0.23 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Neutral
Heatwurx	Very Positive

NanoViricides' return on equity of -87.90% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Heatwurx	N/A	-281.31%	-200.80%

Summary

NanoViricides beats Heatwurx on 7 of the 12 factors compared between the two stocks.

How does Heatwurx compare to Lite Strategy?

Heatwurx (NASDAQ:PCSA) and Lite Strategy (NASDAQ:LITS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Heatwurx has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Lite Strategy has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Heatwurx has higher earnings, but lower revenue than Lite Strategy. Lite Strategy is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Lite Strategy	$65.30M	0.39	-$15.94M	-$1.60	N/A

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 52.4% of Lite Strategy shares are held by institutional investors. 2.4% of Heatwurx shares are held by insiders. Comparatively, 1.6% of Lite Strategy shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Lite Strategy had 1 more articles in the media than Heatwurx. MarketBeat recorded 2 mentions for Lite Strategy and 1 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.87 beat Lite Strategy's score of 0.44 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Very Positive
Lite Strategy	Neutral

Lite Strategy's return on equity of -90.81% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Lite Strategy	N/A	-90.81%	-89.33%

Heatwurx presently has a consensus price target of $25.00, indicating a potential upside of 1,052.07%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than Lite Strategy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lite Strategy	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Heatwurx beats Lite Strategy on 9 of the 14 factors compared between the two stocks.

How does Heatwurx compare to China Pharma?

China Pharma (NYSE:CPHI) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

China Pharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

China Pharma has higher revenue and earnings than Heatwurx. China Pharma is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	7.25	-$3.08M	-$0.55	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

In the previous week, Heatwurx had 1 more articles in the media than China Pharma. MarketBeat recorded 1 mentions for Heatwurx and 0 mentions for China Pharma. Heatwurx's average media sentiment score of 1.87 beat China Pharma's score of 0.32 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
Heatwurx	Very Positive

Heatwurx has a consensus target price of $25.00, indicating a potential upside of 1,052.07%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts clearly believe Heatwurx is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heatwurx has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Heatwurx	N/A	-281.31%	-200.80%

91.9% of Heatwurx shares are owned by institutional investors. 6.4% of China Pharma shares are owned by company insiders. Comparatively, 2.4% of Heatwurx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Heatwurx beats China Pharma on 8 of the 15 factors compared between the two stocks.

How does Heatwurx compare to Tvardi Therapeutics?

Heatwurx (NASDAQ:PCSA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Tvardi Therapeutics' return on equity of -64.17% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Heatwurx has higher earnings, but lower revenue than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Tvardi Therapeutics	$7.14M	3.47	-$18.21M	-$3.10	N/A

Heatwurx has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Tvardi Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Heatwurx presently has a consensus price target of $25.00, indicating a potential upside of 1,052.07%. Tvardi Therapeutics has a consensus price target of $39.80, indicating a potential upside of 1,407.58%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 2.4% of Heatwurx shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Tvardi Therapeutics had 7 more articles in the media than Heatwurx. MarketBeat recorded 8 mentions for Tvardi Therapeutics and 1 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.87 beat Tvardi Therapeutics' score of 1.24 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Very Positive
Tvardi Therapeutics	Positive

Summary

Tvardi Therapeutics beats Heatwurx on 10 of the 15 factors compared between the two stocks.

How does Heatwurx compare to CervoMed?

Heatwurx (NASDAQ:PCSA) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by insiders. Comparatively, 35.8% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, CervoMed had 7 more articles in the media than Heatwurx. MarketBeat recorded 8 mentions for CervoMed and 1 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.87 beat CervoMed's score of 0.35 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Very Positive
CervoMed	Neutral

Heatwurx has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
CervoMed	-672.80%	-136.08%	-112.62%

Heatwurx has higher earnings, but lower revenue than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
CervoMed	$4.01M	5.66	-$26.97M	-$3.28	N/A

Heatwurx presently has a consensus price target of $25.00, suggesting a potential upside of 1,052.07%. CervoMed has a consensus price target of $22.60, suggesting a potential upside of 822.45%. Given Heatwurx's higher probable upside, research analysts plainly believe Heatwurx is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Heatwurx has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, CervoMed has a beta of -0.68, suggesting that its stock price is 168% less volatile than the broader market.

Summary

CervoMed beats Heatwurx on 8 of the 15 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.97M	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.23	18.84	24.00	24.42
Price / Sales	N/A	455.32	533.77	123.88
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.88	3.98	10.55	6.82
Net Income	-$13.56M	$75.79M	$3.57B	$337.56M
7 Day Performance	-10.33%	1.57%	0.59%	1.16%
1 Month Performance	-26.69%	-0.73%	1.55%	3.16%
1 Year Performance	-66.42%	23.44%	25.41%	30.60%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	4.1659 of 5 stars	$2.30 +6.0%	$25.00 +986.5%	-66.4%	$6.33M	N/A	N/A	20	Positive News Gap Up
NNVC NanoViricides	0.3765 of 5 stars	$1.38 -8.0%	N/A	-19.2%	$29.87M	N/A	N/A	20
LITS Lite Strategy	0.5302 of 5 stars	$0.75 -13.4%	N/A	N/A	$29.41M	$65.30M	N/A	100	Short Interest Increase
CPHI China Pharma	N/A	$0.72 -12.8%	N/A	-56.2%	$29.05M	$3.99M	N/A	250	Gap Up
TVRD Tvardi Therapeutics	3.0804 of 5 stars	$2.89 -6.2%	$53.60 +1,754.7%	-89.3%	$28.90M	$7.14M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors

PCSA vs. NNVC, LITS, CPHI, TVRD, and CRVO

How does Heatwurx compare to NanoViricides?

Summary

How does Heatwurx compare to Lite Strategy?

Summary

How does Heatwurx compare to China Pharma?

Summary

How does Heatwurx compare to Tvardi Therapeutics?

Summary

How does Heatwurx compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heatwurx (PCSA) Competitors

PCSA vs. NNVC, LITS, CPHI, TVRD, and CRVO

How does Heatwurx compare to NanoViricides?

Which has stronger valuation and earnings, NNVC or PCSA?

Which has more risk & volatility, NNVC or PCSA?

Do insiders and institutionals hold more shares of NNVC or PCSA?

Do analysts rate NNVC or PCSA?

Does the media prefer NNVC or PCSA?

Is NNVC or PCSA more profitable?

Summary

How does Heatwurx compare to Lite Strategy?

Which has more volatility & risk, PCSA or LITS?

Which has stronger earnings & valuation, PCSA or LITS?

Do institutionals & insiders believe in PCSA or LITS?

Does the media favor PCSA or LITS?

Is PCSA or LITS more profitable?

Do analysts prefer PCSA or LITS?

Summary

How does Heatwurx compare to China Pharma?

Which has more risk and volatility, CPHI or PCSA?

Which has higher valuation and earnings, CPHI or PCSA?

Does the media prefer CPHI or PCSA?

Do analysts rate CPHI or PCSA?

Is CPHI or PCSA more profitable?

Do insiders & institutionals hold more shares of CPHI or PCSA?

Summary

How does Heatwurx compare to Tvardi Therapeutics?

Is PCSA or TVRD more profitable?

Which has better valuation & earnings, PCSA or TVRD?

Which has more volatility and risk, PCSA or TVRD?

Do analysts rate PCSA or TVRD?

Do institutionals and insiders believe in PCSA or TVRD?

Does the media refer more to PCSA or TVRD?

Summary

How does Heatwurx compare to CervoMed?

Do insiders & institutionals have more ownership in PCSA or CRVO?

Does the media favor PCSA or CRVO?

Is PCSA or CRVO more profitable?

Which has higher earnings and valuation, PCSA or CRVO?

Do analysts prefer PCSA or CRVO?

Which has more volatility and risk, PCSA or CRVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools